The activation of canonical Wnt/β-catenin signaling in ovarian cancer cells with functional BRCA1 and BRCA2 can confer protumor advantages such as proliferation, survival, and mitochondrial efficiency. This evidence concerns the gene BRCA1 and ovarian carcinoma.